

6. REFERENCES

6. References

- Agarwal, R. (2005). "The acronym "PCP" is pneumocystis pneumonia, not *Pneumocystis carinii* pneumonia." Am J Roentgenol **185**(6): 1653-1654.
- Agnew, J. E. (1984). Physical properties and mechanisms of deposition of aerosols. Aerosols and the Lung: Clinical and Experimental Aspects. S. W. Clarke and D. Pavia. London, UK, Butterworth & Co. Ltd: 49-68.
- American Pharmaceutical Association (1994). Handbook of Pharmaceutical Excipients. Washington/London, American Pharmaceutical Association & Pharmaceutical Press.
- Amidon, G. L., H. Lennernäs, et al. (1995). "A theoretical basis for a biopharmaceutic drug classification: The correlation of *in vitro* drug product dissolution and *in vivo* bioavailability." Pharm Res **12**(3): 413-420.
- Anonymous (1994). "Revised nomenclature for *Pneumocystis carinii*. The *Pneumocystis* Workshop." J Euk Microbiol **41** (suppl.): 121-122.
- Araujo, F. G., J. Huskinson, et al. (1991). "Remarkable *in vitro* and *in vivo* activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of *Toxoplasma gondii*." Antimicrob Agents Ch **35**(2): 293-299.
- Arppe, J., M. Vidgren, et al. (1998). "Pulmonary pharmacokinetics of cyclosporin A liposomes." Int J Pharm **161**(2): 205-214.
- Astra Zeneca (2002). Prescribing Information Pulmicort Respules, Budsonide Inhalation Suspension. USA, Astra Zeneca Group.
- Atkins, P. J., N. P. Barker, et al. (1992). The design and development of inhalation drug delivery systems. Pharmaceutical inhalation aerosol technology. A. J. Hickey. New York, Marcel Dekker, Inc.: 155-185.
- Barreras, F., H. Amaveda, et al. (2002). "Transient high-frequency ultrasonic water atomization." Experiments in Fluids **33**: 405-413.

- Beasley, R., P. Rafferty, et al. (1988). "Adverse reactions to the non-drug constituents of nebuliser solutions." Br. J. clin. Pharmac. **25**: 283-287.
- bene Arzneimittel GmbH (1995). Prescribing information Tacholiquin. Munich Germany, bene Arzneimittel GmbH.
- Beyer, J., S. Schwartz, et al. (1994). "Use of amphotericin B aerosols for the prevention of pulmonary Aspergillosis." Infection **22**: 143-148.
- Bisrat, M. and C. Nyström (1988). "Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions." Int J Pharm **47**: 223-231.
- Blum, T., A. Roth, et al. (2006). "Pneumocystis jiroveci pneumonia in immunocompromised patients without AIDS - a case series." Deut Med Wochenschr **131**(27): 1515-1520.
- Boe, J., J. H. Dennis, et al. (2001). "European Respiratory Society Guidelines on the use of nebulizers: Guidelines prepared by a European Respiratory Society Task Force on the use of nebulizers." Eur Respir J **18**(1): 228-242.
- Böhm, B. (1999). Herstellung und Charakterisierung von Nanosuspensionen als neue Arzneiform für Arzneistoffe mit geringer Bioverfügbarkeit. Pharmazie. Berlin, Germany, PhD Thesis. Freie Universität Berlin: 200p.
- Bozzette, S. A., D. M. Finkelstein, et al. (1995). "A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection." N Engl J Med **332**: 693-699.
- British Pharmacopeia (1998). F. Aerodynamic Assessment of Fine Particles - Fine particle dose and particle size distribution. British Pharmacopeia: A222-A230.
- Broman, E., C. Khoo, et al. (2001). "A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug." Int J Pharm **222**(1): 139-151.
- Carini, A. (1910). "Formas de eschizogonia do *Trypanosoma lewisi*." Soc Med Cir Sao Paulo **38**: 8.

- Carless, J. E. (1977). Solutions. Bentley's textbook of pharmaceuticals. E. A. Rawlins. London, Baillière Tindall: 3-18.
- Centers for Disease Control & Prevention, National Center for Infectious Diseases, et al. (2005). *Pneumocystis* infection (*Pneumocystis jiroveci*). Parasites and Health. Laboratory Identification of Parasites of Publish Health Concern.
- Chagas, C. (1909). "Nova tripanomia zaea humana. Ueber eine neve trypano somiasis de menschen." Mem Inst Oswaldo Cruz **1**: 159-218.
- Chan, C., J. Montaner, et al. (1999). "Atovaquone suspension compared with aerosolized pentamidine for Prevention of *Pneumocystis carinii* Pneumonia in Human Immunodeficiency virus-infected subjects intolerant of Trimethoprim or Sulfonamides." J Infect Dis **180**: 169-176.
- Chiodini, P. L., C. P. Conlon, et al. (1995). "Evaluation of atovaquone in the treatment of patients with uncomplicated *Plasmodium falciparum* malaria." J Antimicrob Chemother **36**(6): 1073-1078.
- Chokshi, R. J., H. K. Sandhu, et al. (2005). "Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion process as a means to manufacture solid dispersion/solution." J Pharm Sci **94**(11): 2463-2474.
- Clarke, S. W. (1984). Anatomy and physiology of the human lung: aspects relevant to aerosols. Aerosols and the Lung: Clinical and Experimental Aspects. S. W. Clarke and D. Pavia. London, UK, Butterworth & Co. Ltd: 1-17.
- Contini, C., M. P. Villa, et al. (1998). "Detection of *Pneumocystis carinii* among children with chronic respiratory disorders in the absence of HIV infection and immunodeficiency." J Med Microbiol **47**(4): 329-333.
- Croft, S. L., J. Hogg, et al. (1992). "The activity of hydroxynaphthoquinones against *Leishmania donovani*." J Antimicrob Chemother **30**(6): 827-832.
- Crowley, K. J. and G. Zografi (2002). "Water vapor absorption into amorphous hydrophobic drug/poly(vinylpyrrolidone) dispersions." J Pharm Sci **91**(10): 2150-2165.

- Cushion, M. T. (1994). Transmission and epidemiology. *Pneumocystis carinii* pneumonia. P. D. Walzer. New York, USA, Marcel Dekker, Inc.: 25-43.
- Cushion, M. T. (1998). *Pneumocystis carinii*. Topley and Wilson's Microbiology and Microbial Infections. L. Collier, A. Ballows and M. Sussman. New York, USA, Arnold Publishing. **4**: 674.
- Cushion, M. T. (2004). "Pneumocystis: unraveling the cloak of obscurity." Trends Microbiol **12**(5): 243-249.
- de Boer, A. H., D. Gjaltema, et al. (2002). "Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique." Int J Pharm **249**: 219-231.
- de Boer, A. H., D. Gjaltema, et al. (2002). "Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols." Int J Pharm **249**: 233-245.
- Dennis, J. H. (1994). Drug nebuliser design and performance: breath enhanced versus constant output jet versus ultrasonic. Proceedings of Drug Delivery to the Lungs V, London, U.K., The Aerosol Society.
- Dennis, J. H. and D. J. Hendrick (1992). "Design characteristics for drug nebulizers." J Med Eng Technol **16**(2): 63-68.
- Dhar, S., D. V. Malhotra, et al. (1986). "Chemotherapy of *Theileria annulata* infection with buparvaquone." Vet Rec **119**: 635-636.
- Dolovich, M. (1989). "Physical Principles Underlying Aerosol Therapy." J Aerosol Med **2**(2): 171-186.
- Durand Jolie, I., E. M. Aliouat, et al. (2002). "*Pneumocystis carinii* f. sp. *hominis* is not infectious for SCID mice." J Clin Microbiol **40**: 1862-1865.
- Edman, J. C., J. A. Kovacs, et al. (1988). "Ribosomal rRNA sequence shows *Pneumocystis-carinii* to be a member of the fungi." Nature **334**(6182): 519-522.

- Edwards, D. A., J. Hanes, et al. (1997). "Large porous particles for pulmonary drug delivery." Science **276**: 1868-1871.
- El-Sadr, W. M., R. L. Murphy, et al. (1998). "Atovaquone compared with Dapsone for the prevention of *Pneumocystis carinii* pneumonia in patients with HIV infection who cannot tolerate Trimethoprim, Sulfonamides, or both." N Eng J Med **339**: 1889-1995.
- European Pharmacopeia (1997). 2.2.9 Capillary viscometer method. European Pharmacopeia: 27-28.
- European Pharmacopeia (1997). 2.9.18. Preparations for Inhalation: Aerodynamic Assessment of Fine particles. European Pharmacopeia: 143-150.
- Ferron, G. A., C. Roth, et al. (1997). "Estimation of the size distribution of aerosols produced by jet nebulizers as a function of time." J Aerosol Sci **28**(5): 805-819.
- Ferron, G. A. and S. C. Soderholm (1990). "Estimation of the times for evaporation of pure water droplets and for stabilization of salt solution particles." J Aerosol Sci **21**(3): 415-429.
- Flandre, T. D. and D. J.-M. Desmecht Double chamber plethysmography in healthy BALB/c and C57CL/6 mice: effect of somatic growth. [Online]. Faculty of Veterinary Medicine. University of Liège.
<http://www.ulg.ac.be/fmv/anapath/plethysmo/tab57.htm#cf> [3 Jan. 2002].
- Flandre, T. D., P. L. Leroy, et al. (2003). "Effect of somatic growth, strain, and sex on double-chamber plethysmographic respiratory function values in healthy mice." J Appl Physiol **94**(3): 1129-1136.
- Frenkel, J. K. (1999). "*Pneumocystis* pneumonia, an immunodeficiency-dependent disease (IDD): a critical historical overview." J Euk Microbiol **46**: 89S-92S.
- Fry, M., A. T. Hudson, et al. (1984). "Potent and selective hydroxynaphthoquinone inhibitors of mitochondrial electron transport in *Eimeria tenella* (Apicomplexa: Coccidia)." Biochem Pharmacol **33**(13): 2115-2122.

- Fuchs, N. A. and A. G. Sutugin (1966). Generation and use of monodisperse aerosols. Aerosol Science. e. C. N. Davies. New York, Academic Press: 1-30.
- Fukaya, H., A. Iimura, et al. (2003). "A cyclosporin A/maltosyl- α -cyclodextrin complex for inhalation therapy of asthma." Eur Respir J **22**(2): 213-219.
- Gigliotti, F., A. G. Harmsen, et al. (1993). "*Pneumocystis carinii* is not universally transmissible between mammalian species." Infect Immun **61**(7): 2886-2890.
- Glas-Col[®] (2000). Inhalation Exposure System User Instructions. IN, USA.
- GlaxoSmithKline (2001). Prescribing information Mepron (atovaquone) suspension. Research Triangle Park, North Carolina, USA, GlaxoSmithKline.
- Gonda, I. (1988). Therapeutic aerosols. Pharmaceutics: The science of dosage form design. M. E. Aulton. London, UK: 341-358.
- Gordon, M. and J. S. Taylor (1952). "Ideal co-polymers and the second order transitions of synthetic rubbers. I. Non-crystalline co-polymers." J Appl Chem **2**: 493-500.
- Gordon, S. M., S. P. LaRosa, et al. (1999). "Should prophylaxis for *Pneumocystis carinii* pneumonia in solid organ transplant recipients ever be discontinued?" Clin Infect Dis **28**(2): 240-246.
- Granero, G. and M. Longhi (2002). "Thermal analysis and spectroscopic characterization of interactions between a naphthoquinone derivate with HP-beta-CD or PVP." Pharm Dev Technol **7**(3): 380-391.
- Gronenberg, D. A., C. Witt, et al. (2003). "Fundamentals of pulmonary drug delivery." Resp Med **97**: 382-387.
- Hancock, B. C. and G. Zografi (1997). "Characteristics and significance of the amorphous state in pharmaceutical systems." J Pharm Sci **86**(1): 1-12.
- Hannan, S. L., G. A. Ridout, et al. (1996). "Determination of the potent antiprotozoal compound atovaquone in plasma using liquid-liquid extraction followed by reversed-phase high-performance liquid chromatography with ultraviolet detection." J Chromatogr B **678**: 297-302.

- Hernández-Trejo, N., A. H. de Boer, et al. (2005). Buparvaquone nanosuspension for inhalation: Formulation strategies and behavior during jet nebulisation. Proceedings of the 32nd Annual Meeting & Exposition of the Controlled Release Society, Miami Beach, Florida, U.S.A.
- Hernández-Trejo, N., O. Kayser, et al. (2005). "Characterization of nebulized buparvaquone nanosuspensions - effect of nebulization technology." Journal of Drug Targeting **13**(8-9): 499-507.
- Hernández-Trejo, N., O. Kayser, et al. (2005). "Characterization of nebulized buparvaquone nanosuspensions - effect of nebulization technology." J Drug Target **13**(8-9): 499-507.
- Hess, D. (2000). "Nebulisers: Principles and Performance." Respir Care **45**(6): 609-622.
- Hess, D., D. Fisher, et al. (1996). "Medication Nebulizer Performance. Effects of Diluent volume, Nebulizer flow and Nebulizer brand." Chest **110**(2): 498-505.
- Hickey, A. J. (1992). Methods of aerosol particle size characterization. Pharmaceutical inhalation aerosol technology. A. J. Hickey. New York, Marcel Dekker, Inc.: 219-253.
- Hickey, A. J. and D. C. Thompson (1992). Physiology of the Airways. Pharmaceutical inhalation aerosol technology. A. J. Hickey. New York, Marcel Dekker, Inc.: 1-27.
- Hinrichs, W. L. J., M. G. Prinsen, et al. (2001). "Inulin glasses for the stabilization of therapeutic proteins." Int J Pharm **215**(1-2): 163-174.
- Höffken, G., G. Bähge, et al. (1999). "Pathogenese der *Pneumocystis carinii* Pneumonie." Pneumologie **53**: 530-538.
- Hudson, A. T. and A. W. Randall (1982). 1,4-Naphthoquinones, methods for their preparation, pharmaceutical and veterinary formulations thereof. Europe.

- Hudson, A. T., A. W. Randall, et al. (1985). "Novel anti-malarial hydroxynaphthoquinones with potent broad spectrum anti-protozoal activity." Parasitology **90**: 45-55.
- Hughes, W., G. Leoung, et al. (1993). "Comparison of Atovaquone (566C80) with Trimethoprim-Sulfamethoxazole to treat *Pneumocystis Carinii* Pneumonia in patients with AIDS." N Eng J Med **328**(21): 1521-1527.
- Hughes, W. T. (1978). "Pneumocystis pneumonia: a plague of the immunosuppressed." John Hopkins Med J **143**: 184-192.
- Hughes, W. T. (1982). "Natural mode of acquisition for the *de novo* infection with *Pneumocystis carinii*." J Infect Dis **145**: 824-848.
- Hughes, W. T., S. Feldman, et al. (1975). "Intensity of immunosuppressive therapy and the incidence of *Pneumocystis carinii* pneumonitis." Cancer **36**: 2004-2009.
- Hughes, W. T., V. L. Gray, et al. (1990). "Efficacy of a hydroxynaphthoquinone, 566C80, in experimental *Pneumocystis carinii* pneumonitis." Antimicrob Agents Ch **34**(2): 225-228.
- Hughes, W. T., S. W. LaFon, et al. (1995). "Adverse Events Associated with Trimethoprim-Sulfamethoxazole and Atovaquone during the Treatment of AIDS-Related *Pneumocystis carinii* Pneumonia." J Infect Dis **171**: 1295-1301.
- Hughes, W. T., E. M. Sillos, et al. (1998). "Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine *Pneumocystis carinii* Pneumonia." J Infect Dis **177**: 1046-1056.
- Jacobs, C., O. Kayser, et al. (2001). "Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone." Int J Pharm **214**(1-2): 3-7.
- Jacobs, C. and R. H. Müller (2002). "Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration." Pharm Res **19**(2): 189-194.

- Jirovec, O. (1952). "*Pneumocystis carinii* puvodce t. zv intertialnich plasmocelularnich pneumonii kojencw [*Pneumocystis carinii*, the cause of interstitial plasmacellular pneumonia in neonates]." Csl Hyg Epid Mikrob **1**: 141.
- Johnson, J. E. and J. R. Phil (1977). "The defense of the lung: studies of the roll of cell-mediated immunity." John Hopkins Med J **141**: 126-134.
- Kaneshiro, E. S., M. Basselin, et al. (2006). "Ubiquinone synthesis and its regulation in *Pneumocystis carinii*." J Eukaryot Microbiol **53**(6): 436-444.
- Kaneshiro, E. S., D. Sul, et al. (2001). "Pneumocystis carinii synthesizes four ubiquinone homologs: inhibition by Atovaquone and Buparvaquone but not by Stigmatellin." J Eukaryot Microbiol **Suppl.**: 172S-173S.
- Kaneshiro, E. S., D. Sul, et al. (2000). "Effects of atovaquone and diospyrin-based drugs on ubiquinone biosynthesis in *Pneumocystis carinii* organisms." Antimicrob Agents Ch **44**(1): 14-18.
- Kayser, O. (2001). "A new approach for targeting to *Cryptosporidium parvum* using mucoadhesive nanosuspensions: research and applications." Int Journal of Pharm **214**(1-2): 83-85.
- Kayser, O. and A. F. Kiderlen (2003). "Delivery strategies for antiparasitics." Expert Opin Investig Drugs **12**(2): 197-207.
- Keck, C. M. (2006). Cyclosporine nanosuspensions: Optimised size characterisation & oral formulations. Pharmazie. Berlin, Freie Universität Berlin.
- Keck, C. M. and R. H. Muller (2006). "Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation." Eur J Pharm Biopharm **62**(1): 3-16.
- Keely, S. P., J. M. Fischer, et al. (2004). "Phylogenetic identification of *Pneumocystis murina* sp. nov., a new species in laboratory mice." Microbiol **150**: 1153-1165.
- Kendrick, A. H., E. C. Smith, et al. (1995). "Nebulisers - fill volume, residual volume and matching of nebuliser to compressor." Respir Med **89**: 157-159.

- Kendrick, A. H., E. C. Smith, et al. (1997). "Selecting and using nebuliser equipment." Thorax **52**(Suppl. 2): S92-S101.
- Kim, C. K., J. M. Foy, et al. (1987). "Comparison of histologic and quantitative techniques in evaluation of therapy for experimental *Pneumocystis carinii* Pneumonia." Antimicrob Agents Ch **31**(2): 197-201.
- Kinabo, L. D. and J. A. Bogan (1988). "Parvaquone and buparvaquone: HPLC analysis and comparative pharmacokinetics in cattle." Acta Trop **45**(1): 87-94.
- Kipp, J. E., J. C. T. Wong, et al. (2003). Microprecipitation method for preparing submicron suspensions. US Patent No. 6,607,784.
- Klein, N. C., F. P. Duncanson, et al. (1992). "Trimethoprim-sulfamethoxazole versus pentamidine for *Pneumocystis carinii* pneumonia in AIDS patients: results of a large prospective randomized treatment trial." AIDS **6**: 301-305.
- Kraft, W. K., B. Steiger, et al. (2004). "The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers." J Clin Pharmacol **44**(1): 67-72.
- Laube, U. and A. F. Kiderlen (1998). "Detection of parasites with DNA-binding bisbenzimidazole H33258 in *Pneumocystis carinii*- and *Leishmania*- containing materials." Parasitol Res **84**: 559-564.
- Ledermüller, R., R. Stangl, et al. (2003). "Nebulizer technology." Business briefing: Global Healthcare: 1-4.
- Leong, K. H. (1992). Theoretical principles and devices used to generate aerosols for research. Pharmaceutical inhalation aerosol technology. A. J. Hickey. New York, Marcel Dekker, Inc.: 129-153.
- Lintz, F.-C., E. Walther, et al. (2002). Use of a Knowledge Based System (KBS) to shorten and streamline development of nebulizer formulations. Respiratory Drug Delivery VIII, Virginia Commonwealth University School of Pharmacy, Tucson, Arizona.

- Liversidge, G. G., K. C. Cundy, et al. (1992). Surface modified drug nanoparticles. US Patent No. 5,145,684.
- Lloyd, V. A. (1996). Inhalation Products. Secundum Artem: Current & Practical Compounding Information for the Pharmacist. **6**.
- Malvern Instruments, L. (1998). Measuring the zeta potential and particle size using the Malvern Zetasizer 3. Malvern, Uk, Malvern Instruments Ltd.
- Malvern Instruments, L. (2004). Zeta Potential Theory. Zetasizer NanoSeries User Manual. Malvern, UK. **MAN0317 Issue 2.1**: 16.1-16.11.
- Mäntylä, A., T. Garnier, et al. (2004). "Synthesis, in Vitro Evaluation, and Antileishmanial Activity of Water-Soluble Prodrugs of Buparvaquone." J Med Chem **47**: 188-195.
- Mäntylä, A., J. Rautio, et al. (2004). "Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone." Eur J Pharm Sci **23**(2): 151-158.
- Martin, Y. C., T. M. Bustard, et al. (1973). "Relationship between physical properties and antimalarial activities of 1,4-naphthoquinones." J Med Chem **16**(10): 1089-1093.
- Martonen, T. B. and I. M. Katz (1993). "Deposition Patterns of Aerosolized Drugs Within Human Lungs: Effects of Ventilatory Parameters." Pharm Res **10**(6): 871-878.
- McAllister, S. M., H. O. Alpar, et al. (1996). "Do interactions with phospholipids contribute to the prolonged retention of polypeptides within the lung?" Adv Drug Deliver Rev **19**(1): 89-110.
- McCallion, O. N. M. and M. J. Patel (1996). "Viscosity effects on nebulisation of aqueous solutions." Int J Pharm **130**(2): 245-249.
- McCallion, O. N. M., K. M. G. Taylor, et al. (1994). "Nebulising fluids of different physicochemical properties." Eur J Pharm Sci **2**: 183.

- McCallion, O. N. M., K. M. G. Taylor, et al. (1995). "Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers." Pharm Res **12**(11): 1682-1688.
- McCallion, O. N. M., K. M. G. Taylor, et al. (1996). "Nebulisation of monodisperse latex sphere suspensions in air-jet and ultrasonic nebulisers." Int J Pharm **133**: 203-214.
- McHardy, N. (1988). Buparvaquone, the new antitheilerial: A review of its efficacy and safety. Theileriosis in Eastern, Central and Southern Africa: Proceedings of a Workshop on East Coast Fever Immunization, Lilongwe, Malawi, The International Laboratory for Research on Animal Diseases (ILRAD).
- McHardy, N., L. S. Wekesa, et al. (1985). "Antitheilerial activity of BW720C (buparvaquone): a comparison with parvaquone." Res Vet Sci **39**: 29-33.
- Meuwissen, J. H., I. Tauber, et al. (1977). "Parasitologic and serologic observations of infection with *Pneumocystis* in humans." J Infect Dis **136**(1): 43-49.
- Minami, T. M., T. Nakano, et al. (1985). "Efficacy of naphthoquinones and imidocarb dipropionate on *Theileria sergenti* infections in splenectomized calves." Jpn J Vet Sci **47**: 297-300.
- Minter, B. (2003). Opportunities in drug delivery: Identifying hot technologies, companies and markets, Urch Publishing Ltd.
- Mitchell, J. P., M. W. Nagel, et al. (2003). "An in Vitro Study to Investigate the Use of a Breath-Actuated, Small-Volume, Pneumatic Nebulizer for the Delivery of Methacholine Chloride Bronchoprovocation Agent." Respir Care **48**(1): 46-51.
- Monk, J. P. and P. Benfield (1990). "Inhaled pentamidine: an overview of its pharmacological properties and a review of its therapeutic use in *Pneumocystis carinii* pneumonia." Drugs **39**: 741-756.
- Mosharraf, M. and C. Nystrom (1995). "The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs." Int J Pharm **122**(1-2): 35-47.

- Müller, R. H. (1996). Zetapotential und Partikelladung in der Laborpraxis. Einführung in die Theorie Praktische Meßdurchführung Dateninterpretation. Stuttgart, Germany, Wissenschaftliche Verlagsgesellschaft mbH.
- Müller, R. H., R. Becker, et al. (1994). Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit. German Patent No. P4440337.2.
- Müller, R. H., R. Becker, et al. (1999). Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of dissolution. US Patent No. 5,858,410.
- Müller, R. H. and B. H. L. Böhm (1998). Nanosuspensions. Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs. R. H. Müller, S. Benita and B. Böhm. Stuttgart, Medpharm Scientific: 149-174.
- Müller, R. H., C. Jacobs, et al. (2001). "Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future." Adv Drug Deliver Rev **47**: 3-19.
- Müller, R. H., K. Mäder, et al. (2000). Verfahren zur schonenden Herstellung von hochfeinen Micro-/Nanopartikeln. Germany.
- Nerbrink, O., M. Dahlback, et al. (1994). "Why do medical nebulisers differ in their output and particle size characteristics?" J Aerosol Med **7**(259-276).
- Neuberger, D. and J. Wong (2005). "Suspension for intravenous injection: image analysis of scanning electron micrographs of particles to determine size and volume." PDA J Pharm Sci Technol **59**(3): 187-199.
- Newman, S., P. Pellow, et al. (1985). "Evaluation of jet nebulisers for use with gentamicin solution." Thorax **40**: 671-676.
- Newman, S. P. (1984). Therapeutic aerosols. Aerosols and the Lung: Clinical and Experimental Aspects. S. W. Clarke and D. Pavia. London, UK, Butterworth & Co. Ltd: 199-224.

- Newman, S. P. (1985). "Aerosol deposition considerations in inhalation therapy." Chest **88**(Supplement 1): 52S - 60S.
- Newman, S. P. (2000). "Lung deposition from nebulizers." Eur Respir Rev **10**(72): 224-227.
- Newman, S. P. and S. W. Clarke (1983). "Therapeutic aerosols I -physical and practical considerations." Thorax **38**: 881-886.
- Newman, S. P., G. Woodman, et al. (1988). "Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern." Thorax **43**: 318-322.
- Nikander, K., M. Turpeinen, et al. (1999). "The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension." J Aerosol Med **12**: 47-53.
- Niness, K. R. (1999). "Inulin and Oligofructose: What Are They?" J Nutr **129**(7): 1402.
- O' Callaghan, C. and P. W. Barry (1997). "The science of nebulised drug delivery." Thorax **52**((Suppl 2)): S31-S44.
- Ostrander, K. D., W. H. Bosch, et al. (1999). "An in-vitro assessment of a NanoCrystal™ beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization." Eur J Pharm Biopharm **48**: 207-215.
- Patton, J. S. (1996). "Mechanisms of macromolecule absorption by the lungs." Adv Drug Deliver Rev **19**(1): 3-36.
- Patton, J. S., C. S. Fishburn, et al. (2004). "The lungs as a portal of entry for systemic drug delivery." Proc Am Thorac Soc **1**: 338-344.
- Pesanti, E. L. (1994). Host defense effector mechanism and *Pneumocystis carinii*. *Pneumocystis carinii* pneumonia. P. D. Walzer. New York, USA, Marcel Dekker, Inc.: 289-315.
- Peters, K., S. Leitzke, et al. (2000). "Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine *Mycobacterium avium* infection." J Antimicrob Chemoth **45**: 77-83.

- Phair, J., A. Munoz, et al. (1990). "The risk of *Pneumocystis carinii* pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group." N Engl J Med **322**(3): 161-165.
- Phalen, R. F., H.-C. Yeh, et al. (1995). Morphology of the respiratory tract. Concepts in Inhalation Toxicology. R. O. McClellan and H. R. F. London, UK, Taylor & Francis: 129-149.
- Phipps, P. and I. Gonda (1994). "Evaporation of aqueous aerosols produced by jet nebulisers: effects on particle size and concentration of solution in the droplets." J Aerosol Med **7**: 239-258.
- Phipps, P. R., I. Gonda, et al. (1994). "Regional deposition of saline aerosols of different tonicities in normal and asthmatic subjects." Eur Respir J **7**: 1474-1482.
- Pinto-Alphandary, H., A. Andremont, et al. (2000). "Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications." Int J Antimicrob Ag **13**(3): 155-168.
- Porstendörfer, J., J. Gebhart, et al. (1977). "Effect of evaporation on the size distribution of nebulised aerosols." J Aerosol Sci **8**: 371-380.
- Raabe, O. G., M. A. Al-Bayati, et al. (1988). "Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals." Ann Occup Hyg **32**(Supplement 1 *Inhaled Particles VI*): 53-63.
- Rabinow, B. E. (2004). "Nanosuspensions in drug delivery." Nat Rev **3**: 785-796.
- Rabinow, B. E. and et.al. (2003). Enhanced efficacy of NANOEDGE itraconazole nanosuspension in an immunosuppressed rat model infected with an itraconazole-resistant *C. albicans* strain. Abstracts of the American Association of Pharmaceutical Scientists Annual Meeting, Salt Lake City, Utah.
- Rasenack, N., H. Steckel, et al. (2004). "Preparation of microcrystals by in situ micronization." Powder Technol **143-144**: 291-296.
- Riddick, T. M. (1968). Zeta-Meter Manual. New York, Zeta-Meter Inc.

- Rudolph, C., A. Ortiz, et al. (2005). "Methodological optimization of polyethylenimine (PEI)-based gene delivery to the lungs of mice via aerosol application." J Gene Med **7**(1): 59-66.
- Rudolph, G., R. Kobrich, et al. (1990). "Modeling and Algebraic formulation of regional aerosol deposition in man." J Aerosol Sci **21**(Suppl. 1): S306-S406.
- Ruffolo, J. J. (1994). *Pneumocystis carinii* Cell Structure. Pneumocystis carinii pneumonia. P. D. Walzer. New York, USA, Marcel Dekker, Inc.: 25-43.
- Saah, A. J., D. R. Hoover, et al. (1995). "Predictors for failure of *Pneumocystis carinii* Pneumonia Prophylaxis." JAMA **273**(15): 1197-1202.
- Saulsbury, F. T., M. T. Bernstein, et al. (1979). "*Pneumocystis carinii* pneumonia as the presenting infection in congenital hypogammaglobulinemia." J Pediatr **95**: 559-561.
- Schneider, M., M. E., J. C. C. Borleffs, et al. (1999). "Discontinuation of prophylaxis for *Pneumocystis carinii* pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy." The Lancet **353**: 201-203.
- Schöler, N., K. Krause, et al. (2001). "Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis." Antimicrob Agents Ch **45**(6): 1771-1779.
- Serajuddin, A. T. M. (1999). "Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs." J Pharm Sci **88**(10): 1058-1066.
- Sidman, C. L. and J. B. Roths (1994). New animal models for *Pneumocystis carinii* research: Immunodeficient mice. Pneumocystis carinii pneumonia. P. D. Walzer. New York, USA, Marcel Dekker, Inc.: 223-235.
- Silkstone, V. L. (1999). In-vivo and in-vitro studies to assess the performance of nebulisers : in-vivo lung deposition following inhalation of salbutamol by metered dose inhaler, spacer and nebuliser (jet and ultrasonic). In-vitro characterisation: low flow cascade impaction and aerosol output. Department of Pharmaceutical Technology. Bradford, UK, University of Bradford: 306.

- Simonds, A., S. Newman, et al. (1990). "Alveolar targeting of aerosol pentamidine. Toward a rational delivery system." Am Rev Respir Dis **141**(4 Pt 1): 827-829.
- Skiba, M., F. Bounoure, et al. (2005). "Development of cyclodextrin microspheres for pulmonary drug delivery." J Pharm Pharmaceut Sci **8**(3): 409-418.
- Smulian, G. A., M. J. Linke, et al. (1994). "Analysis of *Pneumocystis carinii* organism burden, viability and antigens in bronchoalveolar lavage fluid in AIDS patients with pneumocytosis: correlation with disease severity." AIDS **8**: 1555-1562.
- Sonner, C., Y.-F. Maa, et al. (2002). "Spray-freeze-drying for protein powder preparation: Particle characterization and a case study with trypsinogen stability." J Pharm Sci **91**(10): 2122-2139.
- Stapleton, K. W. and W. H. Finlay (1998). "Errors in characterizing nebulized particle size distributions with cascade impactors." J Aerosol Med **11**(Supplement 1).
- Steckel, H. and H. G. Brandes (2004). "A novel spray-drying technique to produce low density particles for pulmonary delivery." International Journal of Pharmaceutics **278**(1): 187-195.
- Steckel, H. and F. Eskandar (2003). "Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers." European Journal of Pharmaceutical Sciences **19**: 443-455.
- Steckel, H., J. Thies, et al. (1997). "Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide." Int J Pharm **152**: 99-110.
- Stringer, J. R. (1993). "The identity of *Pneumocystis carinii*: not a single protozoan, but a diverse group of exotic fungi." Infect Agents Dis **2**(3): 109-117.
- Stringer, J. R., C. B. Beard, et al. (2002). "A new name (*Pneumocystis jiroveci*) for *Pneumocystis* from Humans." Emerg Infect Dis **8**(9): 891-896.
- Stringer, S. L., J. R. Stringer, et al. (1989). "*Pneumocystis carinii*: sequence from ribosomal RNA implies a close relationship with fungi." Exp Parasitol **68**(4): 450-461.

- Sweetman, S. C. (2004). Martindale: The Complete Drug Reference. London, Pharmaceutical Press.
- Tarara, T. E., M. S. Hartman, et al. (2004). "Characterization of suspension-based metered dose inhaler formulations composed of spray dried budesonide microcrystals dispersed in HFA-134a." Pharm Res **21**(9): 1607-1614.
- Taylor, G. and I. Kellaway (2001). Pulmonary drug delivery. Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists. A. M. Hillery, A. W. Lloyd and J. Swarbrick. London, Taylor & Francis: 269-300.
- Technical Committee LBI/37, s. s. a. p. S. (2000). BS ISO 13320-1:1999 Particle size analysis - Laser Diffraction Methods - Part 1: General principles. London, Health Care and Environment Sector Board British Standards Institution: 1-34.
- Thermo Electron Corporation (2003). Series 20-800 Eight stage non-viable impactor. Instruction Manual. Franklin, Massachusetts, US: 33.
- Toma, E., A. Thorne, et al. (1998). "Clindamycin with Primaquine vs. Trimethoprim-Sulfamethoxazole Therapy for Mild and Moderately Severe *Pneumocystis carinii* Pneumonia in Patients with AIDS: A multicenter, double-blind, randomized trial (CTN 004)." Clin Infect Dis **27**: 524-530.
- U.S. Public Health Service and Infectious Diseases Society of America Prevention of Opportunistic Infections Working Group (2002). "Guidelines for preventing opportunistic infections among HIV-infected persons - 2002: Recommendation of the U.S. Public Health Service and the Infectious Diseases Society of America." Centers for Disease Control and Prevention - Morbidity and Mortality Weekly Report **51**(RR-8): 1-52.
- United States Pharmacopeial Convention Inc., C. o. E. (2006). <601> Aerosols, Nasal Sprays, Metered-Dose Inhalers, and Dry Powder Inhalers. The United States Pharmacopeia USP 29; The National Formulary NF 24 through First Supplement. U. S. P. C. Inc. Rockville, MD, USA, Board of Trustees. **29**: 2617.
- United States Pharmacopeial Convention Inc., C. o. E. (2006). <911> Viscosity. The United States Pharmacopeia USP 29; The National Formulary NF 24 through

- First Supplement. U. S. P. C. Inc. Rockville, MD, USA, Board of Trustees. **29**: 2002-2003.
- United States Pharmacopeial Convention Inc., C. o. E. (2006). <941> X-Ray diffraction. The United States Pharmacopeia USP 29; The National Formulary NF 24 through First Supplement. U. S. P. C. Inc. Rockville, MD, USA, Board of Trustees. **29**.
- van Drooge, D.-J., W. L. J. Hinrichs, et al. (2005). "Spray freeze drying to produce a stable [Δ]9-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation." Eur J Pharm Sci **26**(2): 231-240.
- van Drooge, D. J., W. L. J. Hinrichs, et al. (2004). "Anomalous dissolution behaviour of tablets prepared from sugar glass-based solid dispersions." J Control Release **97**(3): 441-452.
- van Drooge, D. J., W. L. J. Hinrichs, et al. (2004). "Incorporation of lipophilic drugs in sugar glasses by lyophilization using a mixture of water and tertiary butyl alcohol as solvent." J Pharm Sci **93**(3): 713-725.
- van Drooge, D. J., W. L. J. Hinrichs, et al. (2006). "Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques." Int J Pharm **310**(1-2): 220-229.
- van Drooge, D. J., W. L. J. Hinrichs, et al. (2004). "Solid dispersions based on inulin for the stabilisation and formulation of [Δ]9-tetrahydrocannabinol." Eur J Pharm Sci **21**(4): 511-518.
- Vanek, J., O. Jirovec, et al. (1953). "Interstitial plasma cell pneumonia in infants." Ann Paediatrici **180**: 1-21.
- Wakefield, A. E. (2002). "Pneumocystis carinii." Br Med Bull **61**: 175-188.
- Waldrep, J. C., J. Arppe, et al. (1997). "High dose cyclosporin A and budesonide-liposome aerosols." Int J Pharm **152**(1): 27-36.

- Walzer, P. D., J. Runck, et al. (1997). "Immunodeficient and immunosuppressed mice as models to test anti-*Pneumocystis carinii* drugs." Antimicrob Agents Ch **41**(2): 251-258.
- Washington, C. (1992). Particle size analysis in pharmaceuticals and other industries. Theory and practice. Great Britain, Ellis Horwood Ltd.
- Wazir, J. F. and N. A. Ansari (2004). "Pneumocystis carinii Infection Update and Review." Arch Pathol Lab Med **128**: 1023-1027.
- Weuts, I., D. Kempen, et al. (2004). "Phase behaviour analysis of solid dispersions of loperamide and two structurally related compounds with the polymers PVP-K30 and PVP-VA64." Eur J Pharm Sci **22**(5): 375-385.
- White, S., D. B. Bennett, et al. (2005). "Exubera: Pharmaceutical development of a novel product for pulmonary delivery of insulin." Diabetes technology & therapeutics **7**(6): 896-906.
- Wilkie, G. M., C. G. D. Brown, et al. (1998). "Chemoprophylaxis of Theileria annulata and Theileria parva infections of calves with buparvaquone." Vet Parasitol **78**(1): 1-12.
- Wood, W. R. and A. L. Loomis (1927). "The physical and biological effects of high frequency sound-waves of great intensity." Phil Mag **4**(417-437).
- Xu, R. (1997). Improvements in particle size analysis using light scattering. Particle and surface characterisation methods. R. H. Müller and W. Mehnert. Stuttgart, Medpharm Scientific: 27-56.
- Yoshiyama, Y., T. Yazaki, et al. (2002). The nebulization of budesonide suspensions by a newly designed mesh nebulizer. Respiratory Drug Delivery VIII. R. N. Dalby, P. R. Byron, J. Peart and S. F. Farr. Raleigh, NC., Davis Horwood International Publishing: 487-489.
- Yu, Z., T. L. Rogers, et al. (2002). "Preparation and characterization of microparticles containing peptide produced by a novel process: spray freezing into liquid." Eur J Pharm Biopharm **54**(2): 221-228.

Zar, J. H. (1984). Biostatistical analysis. New Jersey, USA, Prentice-Hall International Inc.